Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Sulphonamides Market

Sulphonamides Market Size, Share & Trends Analysis Report, By Product Type (Sulfamethoxazole, Sulfadiazine, Sulfisoxazole, Sulfacetamide, Sulfadoxine, Others), By Route of Administration (Oral, Topical, Injectable), By Application (Bacterial Infections, Parasitic Infections, Dermatological Conditions, Ophthalmic Infections), Forecast Period (2026-2035)

Published: May 2026 | Report Code: OMR2029484 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

Sulphonamides market is projected to grow from $1.4 billion in 2025 to $2.2 billion by 2035, expanding at a CAGR of 4.6% during 2026–2035. Sulphonamides are among the earliest classes of antimicrobial drugs and continue to play a crucial role in treating bacterial and parasitic infections, particularly in cost-sensitive healthcare systems.

A key growth driver is the persistent global burden of infectious diseases. According to the World Health Organization, infectious diseases such as lower respiratory infections remain among the leading causes of death globally, particularly in developing regions. Additionally, the International Federation of Pharmaceutical Manufacturers & Associations reports that access to essential medicines, including antibiotics, is expanding through global health initiatives, further supporting demand.

Major end-use industries include hospitals, clinics, and primary healthcare systems, where sulphonamides are widely used for treating urinary tract infections, respiratory infections, and opportunistic infections. The market also benefits from increasing generic drug penetration and the affordability of sulphonamides compared to newer antibiotic classes.

Market Dynamics

Rising Burden of Infectious Diseases Driving Demand

The increasing prevalence of infectious diseases globally is a primary driver for the sulphonamides market. The World Health Organization estimates that infectious diseases continue to account for a significant share of global mortality, especially in low-income countries. Additionally, the IQVIA highlights that antibiotic usage remains high in emerging markets due to population growth and improving healthcare access.

The demand for affordable antibiotics has intensified, particularly in regions where healthcare budgets are constrained. Sulphonamides, being cost-effective and widely available as generics, remain a preferred choice. In 2025–2026, companies such as Teva Pharmaceutical Industries Ltd. and Viatris Inc. are expanding production capacities and strengthening distribution networks to meet rising global demand. Additionally, increased awareness of antimicrobial resistance is encouraging the use of combination therapies, further boosting market growth.

Challenges from Antibiotic Resistance and Pricing Pressure

Despite steady demand, the market faces challenges from rising antimicrobial resistance and pricing pressures. The World Health Organization has identified antimicrobial resistance as one of the top global health threats, which may reduce the effectiveness of traditional antibiotics, including sulphonamides.

Furthermore, intense competition among generic manufacturers leads to significant price erosion. The U.S. Food and Drug Administration has also increased regulatory scrutiny on generic drug manufacturing, raising compliance costs for companies. Supply chain disruptions, particularly in API sourcing, further impact production efficiency. To address these challenges, companies are investing in improved formulations, combination therapies, and manufacturing efficiencies. Strategic collaborations and geographic expansion are also being adopted to maintain profitability and market presence.

Market Segmentation

  • Based on the product type, the market is segmented into sulfamethoxazole, sulfadiazine, sulfisoxazole, sulfacetamide, sulfadoxine, and others.
  • Based on the route of administration, the market is segmented into oral, topical, and injectable.
  • Based on the application, the market is segmented into bacterial infections, parasitic infections, dermatological conditions, and ophthalmic infections.

Sulfamethoxazole Segment Leads the Market

The sulfamethoxazole segment dominates the market due to its widespread use in combination therapies, particularly with trimethoprim. This combination is extensively prescribed for urinary tract infections, respiratory infections, and opportunistic infections in immunocompromised patients. The dominance is supported by strong demand in both developed and developing regions, where healthcare providers rely on established and cost-effective antibiotics. Between 2022 and 2026, companies like Sun Pharmaceutical Industries Ltd. and Aurobindo Pharma Limited have expanded their production capacities to meet increasing global demand. Additionally, the availability of sulfamethoxazole in multiple formulations enhances its adoption across diverse healthcare settings.

Oral Segment to Record Strong Growth

The oral route of administration is expected to witness the fastest growth due to its convenience, cost-effectiveness, and high patient compliance. Oral formulations are widely used in outpatient settings and primary healthcare systems. Technological advancements in drug formulation and packaging are improving the stability and shelf life of oral antibiotics. Moreover, increasing investments in generic drug manufacturing and distribution networks are supporting market expansion. Emerging economies are witnessing significant growth in oral antibiotic consumption due to improved healthcare access and rising awareness.

Regional Outlook

The global sulphonamides market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States dominates the sulphonamides market due to advanced healthcare infrastructure and high antibiotic usage. According to the U.S. Food and Drug Administration, the country maintains strict regulatory standards ensuring the availability of safe and effective generic drugs. Additionally, the Pharmaceutical Research and Manufacturers of America highlight strong pharmaceutical R&D investments, supporting innovation and production capacity. The presence of major pharmaceutical companies further strengthens market growth.

India to Record Strong Growth

India is expected to witness significant growth due to its expanding pharmaceutical manufacturing sector. According to the Indian Ministry of Chemicals and Fertilizers, India is one of the largest producers of generic medicines globally. The International Trade Centre also reports increasing pharmaceutical exports, supporting market expansion. Government initiatives to improve healthcare access and infrastructure are further driving demand for affordable antibiotics.

Market Player Outlook

The sulphonamides market is highly competitive and fragmented, characterized by the presence of global and regional generic drug manufacturers. Companies focus on cost efficiency, large-scale production, and distribution network expansion to maintain competitiveness. Key players such as Teva Pharmaceutical Industries Ltd., Viatris Inc., Novartis AG (Sandoz), Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Limited dominate the market through strong product portfolios and global presence.

Recent Developments

  • In March 2026, Hikma Pharma expanded its injectables portfolio in the US and MENA regions, maintaining its position as a key provider of essential hospital-grade sulfonamide anti-infectives.
  • In January 2023, Alkem Laboratories launched Zidavi (Ceftazidime-Avibactam), marking a strategic move into high-end anti-infectives to combat drug resistance, while maintaining its high-volume sulfonamide generic portfolio.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global sulphonamides market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Sulphonamides Market Sales Analysis – Product Type | Route of Administration | Application ($ Million)
  • Sulphonamides Market Size, Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

 2.2.1 Key Sulphonamides Market Trends

 2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Sulphonamides Market

 2.3.1 Competitive Rivalry

 2.3.2 Threat of New Entrants

 2.3.3 Bargaining Power of Suppliers

 2.3.4 Bargaining Power of Buyers

 2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

 3.1.1 Drivers for the Global Sulphonamides Market: Impact Analysis

3.2 Market Pain Points and Challenges

 3.2.1 Restraints for the Global Sulphonamides Market: Impact Analysis

3.3 Market Opportunities

 3.3.1 Opportunities for the Global Sulphonamides Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Sulphonamides Market Size, Market Revenue, and Share by Manufacturers

  • Sulphonamides Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

 4.2.1 Teva Pharmaceutical Industries Ltd.

 4.2.1.1 Overview

 4.2.1.2 Product Portfolio

 4.2.1.3 Financial Analysis

 4.2.1.4 SWOT Analysis

 4.2.1.5 Business Strategy

 4.2.2 Viatris Inc.

 4.2.2.1 Overview

 4.2.2.2 Product Portfolio

 4.2.2.3 Financial Analysis

 4.2.2.4 SWOT Analysis

 4.2.2.5 Business Strategy

 4.2.3 Novartis AG (Sandoz)

 4.2.3.1 Overview

 4.2.3.2 Product Portfolio

 4.2.3.3 Financial Analysis

 4.2.3.4 SWOT Analysis

 4.2.3.5 Business Strategy

 4.2.4 Sun Pharmaceutical Industries Ltd.

 4.2.4.1 Overview

 4.2.4.2 Product Portfolio

 4.2.4.3 Financial Analysis

 4.2.4.4 SWOT Analysis

 4.2.4.5 Business Strategy

 4.2.5 Aurobindo Pharma Limited

 4.2.5.1 Overview

 4.2.5.2 Product Portfolio

 4.2.5.3 Financial Analysis

 4.2.5.4 SWOT Analysis

 4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

 4.3.1 Merger and Acquisition

 4.3.2 Product Launch

 4.3.3 Partnership And Collaboration

  1. Global Sulphonamides Market Sales Analysis by Product Type ($ Million)

5.1 Sulfamethoxazole

5.2 Sulfadiazine

5.3 Sulfisoxazole

5.4 Sulfacetamide

5.5 Sulfadoxine

5.6 Others

  1. Global Sulphonamides Market Sales Analysis by Route of Administration ($ Million)

6.1 Oral

6.2 Topical

6.3 Injectable

  1. Global Sulphonamides Market Sales Analysis by Application ($ Million)

7.1 Bacterial Infections

7.2 Parasitic Infections

7.3 Dermatological Conditions

7.4 Ophthalmic Infections

  1. Regional Analysis

 8.1 North American Sulphonamides Market Sales Analysis – Product Type | Route of Administration | Application | Country ($ Million)

   8.1.1 United States

   8.1.2 Canada

 8.2 European Sulphonamides Market Sales Analysis – Product Type | Route of Administration | Application | Country ($ Million)

   8.2.1 UK

   8.2.2 Germany

   8.2.3 Italy

   8.2.4 Spain

   8.2.5 France

   8.2.6 Russia

   8.2.7 Rest of Europe

 8.3 Asia-Pacific Sulphonamides Market Sales Analysis – Product Type | Route of Administration | Application | Country ($ Million)

   8.3.1 China

   8.3.2 Japan

   8.3.3 South Korea

   8.3.4 India

   8.3.5 Australia & New Zealand

   8.3.6 ASEAN Countries

   8.3.7 Rest of Asia-Pacific

 8.4 Rest of the World Sulphonamides Market Sales Analysis – Product Type | Route of Administration | Application | Country ($ Million)

   8.4.1 Latin America

   8.4.2 Middle East and Africa

  1. Company Profiles

 9.1 Abbott Laboratories

  9.1.1 Quick Facts

  9.1.2 Company Overview

  9.1.3 Product Portfolio

  9.1.4 Business Strategies

 9.2 AdvaCare Pharma

 9.2.1 Quick Facts

 9.2.2 Company Overview

 9.2.3 Product Portfolio

 9.2.4 Business Strategies

 9.3 Akorn Operating Company LLC

 9.3.1 Quick Facts

 9.3.2 Company Overview

 9.3.3 Product Portfolio

 9.3.4 Business Strategies

 9.4 Alkem Laboratories Limited

 9.4.1 Quick Facts

 9.4.2 Company Overview

 9.4.3 Product Portfolio

 9.4.4 Business Strategies

 9.5 Amneal Pharmaceuticals LLC

 9.5.1 Quick Facts

 9.5.2 Company Overview

 9.5.3 Product Portfolio

 9.5.4 Business Strategies

 9.6 Cadila Pharmaceuticals

 9.6.1 Quick Facts

 9.6.2 Company Overview

 9.6.3 Product Portfolio

 9.6.4 Business Strategies

 9.7 Cipla Limited

 9.7.1 Quick Facts

 9.7.2 Company Overview

 9.7.3 Product Portfolio

 9.7.4 Business Strategies

 9.8 F. Hoffmann-La Roche Ltd.

 9.8.1 Quick Facts

 9.8.2 Company Overview

 9.8.3 Product Portfolio

 9.8.4 Business Strategies

 9.9 Glenmark Pharmaceuticals Ltd.

 9.9.1 Quick Facts

 9.9.2 Company Overview

 9.9.3 Product Portfolio

 9.9.4 Business Strategies

 9.10 Hebei Veyong Bio-Chemical Co., Ltd.

 9.10.1 Quick Facts

 9.10.2 Company Overview

 9.10.3 Product Portfolio

 9.10.4 Business Strategies

 9.11 Hikma Pharmaceuticals PLC

 9.11.1 Quick Facts

 9.11.2 Company Overview

 9.11.3 Product Portfolio

 9.11.4 Business Strategies

 9.12 Intas Pharmaceuticals Ltd.

 9.12.1 Quick Facts

 9.12.2 Company Overview

 9.12.3 Product Portfolio

 9.12.4 Business Strategies

 9.13 Lupin Limited

 9.13.1 Quick Facts

 9.13.2 Company Overview

 9.13.3 Product Portfolio

 9.13.4 Business Strategies

 9.14 Shandong Xinhua Pharmaceutical Co., Ltd.

 9.14.1 Quick Facts

 9.14.2 Company Overview

 9.14.3 Product Portfolio

 9.14.4 Business Strategies

 9.15 Torrent Pharmaceuticals Ltd.

 9.15.1 Quick Facts

 9.15.2 Company Overview

 9.15.3 Product Portfolio

 9.15.4 Business Strategies

 9.16 Virchow Laboratories Limited

 9.16.1 Quick Facts

 9.16.2 Company Overview

 9.16.3 Product Portfolio

 9.16.4 Business Strategies

 9.17 Zhejiang Chengyi Pharmaceutical Co., Ltd.

 9.17.1 Quick Facts

 9.17.2 Company Overview

 9.17.3 Product Portfolio

 9.17.4 Business Strategies

 9.18 Zydus Lifesciences Limited

 9.18.1 Quick Facts

 9.18.2 Company Overview

 9.18.3 Product Portfolio

 9.18.4 Business Strategies

 9.19 Bausch Health

 9.19.1 Quick Facts

 9.19.2 Company Overview

 9.19.3 Product Portfolio

 9.19.4 Business Strategies

 9.20 Bimeda Holdings PLC

 9.20.1 Quick Facts

 9.20.2 Company Overview

 9.20.3 Product Portfolio

 9.20.4 Business Strategies

1. Global Sulphonamides Market Research and Analysis by Product Type, 2025–2035 ($ Million)

2. Global Sulfamethoxazole Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

3. Global Sulfadiazine Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

4. Global Sulfisoxazole Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

5. Global Sulfacetamide Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

6. Global Sulfadoxine Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

7. Global Others Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

8. Global Sulphonamides Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

9. Global Oral Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

10. Global Topical Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

11. Global Injectable Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

12. Global Sulphonamides Market Research and Analysis by Application, 2025–2035 ($ Million)

13. Global Sulphonamides for Bacterial Infections Market Research and Analysis by Region, 2025–2035 ($ Million)

14. Global Sulphonamides for Parasitic Infections Market Research and Analysis by Region, 2025–2035 ($ Million)

15. Global Sulphonamides for Dermatological Conditions Market Research and Analysis by Region, 2025–2035 ($ Million)

16. Global Sulphonamides for Ophthalmic Infections Market Research and Analysis by Region, 2025–2035 ($ Million)

17. Global Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

18. North America Sulphonamides Market Research and Analysis by Country, 2025–2035 ($ Million)

19. North America Sulphonamides Market Research and Analysis by Product Type, 2025–2035 ($ Million)

20. North America Sulphonamides Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

21. North America Sulphonamides Market Research and Analysis by Application, 2025–2035 ($ Million)

22. Europe Sulphonamides Market Research and Analysis by Country, 2025–2035 ($ Million)

23. Europe Sulphonamides Market Research and Analysis by Product Type, 2025–2035 ($ Million)

24. Europe Sulphonamides Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

25. Europe Sulphonamides Market Research and Analysis by Application, 2025–2035 ($ Million)

26. Asia-Pacific Sulphonamides Market Research and Analysis by Country, 2025–2035 ($ Million)

27. Asia-Pacific Sulphonamides Market Research and Analysis by Product Type, 2025–2035 ($ Million)

28. Asia-Pacific Sulphonamides Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

29. Asia-Pacific Sulphonamides Market Research and Analysis by Application, 2025–2035 ($ Million)

30. Rest of the World Sulphonamides Market Research and Analysis by Region, 2025–2035 ($ Million)

31. Rest of the World Sulphonamides Market Research and Analysis by Product Type, 2025–2035 ($ Million)

32. Rest of the World Sulphonamides Market Research and Analysis by Route of Administration, 2025–2035 ($ Million)

33. Rest of the World Sulphonamides Market Research and Analysis by Application, 2025–2035 ($ Million)

1. Global Sulphonamides Market Size by Product Type, 2025 vs 2035 (%)

2. Global Sulfamethoxazole Sulphonamides Market Research and Analysis by Region, 2025 vs 2035 (%)

3. Global Sulfadiazine Sulphonamides Market Research and Analysis by Region, 2025 Vs 2035 (%)

4. Global Sulfisoxazole Sulphonamides Market Research and Analysis by Region, 2025 vs 2035 (%)

5. Global Sulfacetamide Sulphonamides Market Research and Analysis by Region, 2025 vs 2035 (%)

6. Global Sulfadoxine Sulphonamides Market Research and Analysis by Region, 2025 vs 2035 (%)

7. Global Others Sulphonamides Market Research and Analysis by Region, 2025 Vs 2035 (%)

8. Global Sulphonamides Market Size by Applications, 2025 vs 2035 (%)

9. Global Oral Sulphonamides Market Research and Analysis by Region, 2025 vs 2035 (%)

10. Global Topical Sulphonamides Market Research and Analysis by Region, 2025 vs 2035 (%)

11. Global Injectable Sulphonamides Market Research and Analysis by Region, 2025 Vs 2035 (%)

12. Global Sulphonamides Market Size by Route of Administration, 2025 vs 2035 (%)

13. Global Sulphonamides for Bacterial Infections Market Research and Analysis by Region, 2025 vs 2035 (%)

14. Global Sulphonamides for Parasitic Infections Market Research and Analysis by Region, 2025 vs 2035 (%)

15. Global Sulphonamides for Dermatological Conditions Market Research and Analysis by Region, 2025 vs 2035 (%)

16. Global Sulphonamides for Ophthalmic Infections Market Research and Analysis by Region, 2025 vs 2035 (%)

17. Global Sulphonamides Market Size by Region, 2025 vs 2035 (%)

18. United States Sulphonamides Market Size, 2025-2035 ($ Million)

19. Canada Sulphonamides Market Size, 2025-2035 ($ Million)

20. UK Sulphonamides Market Size, 2025-2035 ($ Million)

21. France Sulphonamides Market Size, 2025-2035 ($ Million)

22. Germany Sulphonamides Market Size, 2025-2035 ($ Million)

23. Italy Sulphonamides Market Size, 2025-2035 ($ Million)

24. Spain Sulphonamides Market Size, 2025-2035 ($ Million)

25. Russia Sulphonamides Market Size, 2025-2035 ($ Million)

26. India Sulphonamides Market Size, 2025-2035 ($ Million)

27. China Sulphonamides Market Size, 2025-2035 ($ Million)

28. Japan Sulphonamides Market Size, 2025-2035 ($ Million)

29. South Korea Sulphonamides Market Size, 2025-2035 ($ Million)

30. Australia & New Zealand Sulphonamides Market Size, 2025-2035 ($ Million)

31. ASEAN Sulphonamides Market Size, 2025-2035 ($ Million)

32. Rest of Asia-Pacific Sulphonamides Market Size, 2025-2035 ($ Million)

33. Latin America Sulphonamides Market Size, 2025-2035 ($ Million)

34. Middle East & Africa Sulphonamides Market Size, 2025-2035 ($ Million)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The Sulphonamides market was valued at $1.4 billion in 2025 and is projected to reach $2.2 billion by 2035.
The market is expected to grow at a CAGR of 4.6% during the forecast period 2026–2035.
The sulfamethoxazole segment dominates due to its widespread use in combination therapies.
North America, particularly the United States, leads due to advanced healthcare infrastructure and high drug utilization.
Key trends include rising demand for generics, increasing infectious disease burden, and expansion of oral antibiotic formulations.